title: [Effects of pulmonary arterial perfusion with shenqi fuzheng injection on lung injury during cardiopulmonary bypass].
abstract: OBJECTIVE
  To observe the effect of pulmonary arterial perfusion with Shenqi Fuzheng Injection (SFI)on lung injury during cardiopulmonary bypass (CPB).
  
  
  METHODS
  Twenty-two patients with cardiac valvular disease and pulmonary hypertension were randomly divided into the control and the SFI group equally. SFI mixed pure oxygenated blood to the SFI group, and oxygenated blood alone to the control group was perfused via pulmonary artery during CPB. Plasma malondialdehyde (MDA), pulmonary vascular resistance (PVR), ratio of leucocyte counts in venous and arterial blood, and time of mechanical ventilation applied were measured before and at the end of CPB, and 6th, 24th hours after CPB.
  
  
  RESULTS
  After treatment, MDA content and PVR were significantly higher than those before CPB (P < 0.05), and reduced to normal level 24 h after CPB in both groups, but the peak levels were lower in the SFI group than those in the control group (P < 0.05). The leucocyte counts ratio in venous and arterial blood were significantly higher at the end of CPB and 6 h later than those before CPB in both groups (P < 0.05), but the increment were lower in the SFI group than those in the control group (P < 0.05). Furthermore, the applying mechanical ventilation time in the SFI group was 16.1 +/- 5.5 h, significantly shorter than that in the control group (29.1 +/- 6.9 h, P < 0.01).
  
  
  CONCLUSIONS
  Pulmonary arterial perfusion with SFI could alleviate the CPB induced lung injury.
authors.affiliation: Department of Cardiac Surgery, Qilu Hospital of Shandong University, Jinan. songyimd@hotmail.com
authors.forename: Song
authors.initials: S
authors.lastname: Yi
authors.forename: Li
authors.initials: L
authors.lastname: Ran
authors.forename: Xing-hua
authors.initials: XH
authors.lastname: Gu
mesh_terms: D000328:Adult; D000368:Aged; D002315:Cardiopulmonary Bypass / Q000009:adverse effects*; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006349:Heart Valve Diseases / Q000150:complications / Q000601:surgery; D006801:Humans; D006976:Hypertension, Pulmonary / Q000209:etiology / Q000601:surgery; D007261:Infusions, Intra-Arterial; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D008875:Middle Aged; D008517:Phytotherapy; D011651:Pulmonary Artery; D012128:Respiratory Distress Syndrome / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D016896:Treatment Outcome; D014655:Vascular Resistance / Q000187:drug effects
chemical_list: D004365:Drugs, Chinese Herbal; C521737:shenqi fuzheng; D008315:Malondialdehyde